Financings in Brief: ThermoTrex
This article was originally published in The Gray Sheet
ThermoTrex: Firm's Trex Medical subsidiary begins rights offering under which shareholders of ThermoTrex receive 0.10 rights per share of ThermoTrex to purchase one share of Trex Medical at its initial offering price. Trex Medical filed a registration statement in April for its IPO ("The Gray Sheet" April 8, p. 18). The rights are exercisable through June 24, 1996. Closing of the rights offering is contingent upon closing of the initial Trex Medical public offering...
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.